Abstract
Abstract
Teratogenic potential of human drugs is assessed in embryo-fetal development (EFD) studies in two species as per regulatory guidelines. In vitro developmental toxicity assays can be vital in early drug development efforts to distinguish teratogenic potential of drugs, while reducing animal use. Results from two developmental toxicity in vitro assays (rat whole embryo culture assay and mouse embryonic stem cell test), were evaluated for their ability to predict the teratogenic potential of 83 compounds with known EFD outcome in rats. With an integrated model, the sensitivity and specificity for teratogens and/or embryo-lethal drugs in the presence (89% and 54%, respectively) or absence (96% and 52%, respectively) of maternal toxicity were calculated. Based on these results, we propose that a battery of assays be used to screen for potential EFD toxicity and, in combination with reduced in vivo rat EFD studies, be a part of an integrated regulatory risk assessment.
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
